

The Need for Novel Renal Sparing Therapies

Impact of Renal Function on Long-term Outcomes in Kidney Transplantation

Faculty

Paul Keown, MD (Chairman)
University of British Columbia

Philip Halloran, MD
University of Alberta

Christophe Legendre, MD
Hôpital Necker

Sander Florman, MD
Mt. Sinai Medical Center

Vancouver Convention Centre
Exhibition Level
Exhibit Hall A
Tuesday, August 17, 2010
17:30 - 19:00

Sponsored By:



Bristol-Myers Squibb

CTI

Clinical Trial and Consulting Services

XXIII International Congress of The Transplantation Society

CTI

Clinical Trial and Consulting Services

10123 Alliance Road
Cincinnati, OH 45242-9912

**The Need for Novel
Renal Sparing Therapies**

**Impact of Renal Function on Long-term Outcomes
in Kidney Transplantation**

**Vancouver Convention Centre
Exhibition Level
Exhibit Hall A
Tuesday, August 17, 2010
17:30 - 19:00**



Program Overview

Dear Colleagues,

It is my pleasure to invite you to join us in Vancouver for an important symposium entitled "The Need for Novel Renal Sparing Therapies: Impact of Renal Function on Long-term Outcomes in Kidney Transplantation".

Progress in the development of maintenance immunosuppression accounts for much of the short-term success of kidney transplantation achieved over the past twenty-five years. However, there is a clear need for immunosuppressive agents that retain the efficacy of calcineurin inhibitors and spare kidney function and cardiovascular risk. Current investigational strategies have shifted to the identification and control of factors that compromise long-term patient and allograft survival.

The symposium faculty will explore emerging research surrounding important considerations for long-term kidney allograft recipient and graft survival: early renal function, T cell mediated rejection, early calcineurin inhibitor nephrotoxicity, and cardiovascular disease.

The potential role of novel and emerging non-calcineurin inhibitor-based maintenance immunosuppressive regimens to preserve renal function and to mitigate cardiovascular risk will also be discussed.

Please join us for this exciting program.

Sincerely,
Paul Keown, MD, DSc, MBA
Symposium Chairman

Registration Information

There is no fee for registering for this symposium. Though not required, pre-registration is strongly encouraged. Onsite registration can be accepted on a space-availability basis. Registration includes all program materials, and complimentary hors d'oeuvres.

Phone: 00.1.513.598.9290
(08:00 - 17:00h EST)

Email: info@ctifacts.com
(Please send name and be certain to reference the symposium title)

Program Agenda

17:00

Assembly/Reception

17:30

Chairman's Welcome
Paul Keown, MD

17:40

Factors Impacting Long-term Patient and Graft Survival: Renal Function and Cardiovascular Disease
Paul Keown, MD

17:55

New Concepts of T Cell Mediated Rejection
Philip Halloran, MD

18:10

Understanding Early Calcineurin Inhibitor Nephrotoxicity
Christophe Legendre, MD

18:25

Preserving Renal Function: Novel and Emerging Strategies for de novo Maintenance Immunosuppression
Sander Florman, MD

18:40

Interactive Panel Discussion

19:00

Adjournment

Learning Objectives

Following completion of the program, participants will be able to:

- Describe factors impacting long-term renal patient and graft survival following kidney transplantation
- Discuss the impact of T cell mediated rejection as compared to antibody-mediated rejection on long-term graft outcomes following kidney transplantation
- Recognize emerging mechanisms of early calcineurin inhibitor nephrotoxicity
- Discuss the potential role of novel and emerging de novo maintenance immunosuppressive strategies to optimize renal function following kidney transplantation

